drugset

drugset / Trial / NCT00244231

Efficacy and Safety Study of Nidadd in the Management of Hyperlipidemia

NCT00244231 ↗

Phase 3 Completed 70 enrolled Genovate Biotechnology Co., Ltd.

RandomizedParallel-groupDouble-blindTreatment

Summary

To assess the efficacy and safety of Nidadd (extended-release niacin) in patients with hyperlipidemia.

Timeline

Start: 2003-10
Primary completion: —
Completion: 2005-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Nidadd	Unknown	1000 mg	—

Indications